It is of interest to note that development of AITD has been reported to follow treatment with several of the drugs commonly used in MS, including IFN-β and anti-CD52 antibody (alemtuzumab/Campath/Lemtrada). This evidence concerns the gene CD52 and myeloid sarcoma.